KAG-308

产品编号 T15642Cas号 1215192-68-9

KAG-308 is an effective selective and orally active agonist of the EP4 receptor (Ki: 2.57 nM and EC50: 17 nM for human EP4 receptor), more selective over EP1, EP2, EP3, and IP receptor. KAG-308 suppresses colitis and promotes histological mucosal healing, which potently inhibits TNF-α production.

KAG-308

产品编号 T15642Cas号 1215192-68-9

规格	价格	库存
25 mg	询价	10-14周
50 mg	询价	10-14周
100 mg	询价	10-14周

大包装 & 定制

加入购物车

实验操作小课堂

联系我们获取更多批次信息

资源下载

产品操作手册

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性

产品描述	KAG-308 is an effective selective and orally active agonist of the EP4 receptor (Ki: 2.57 nM and EC50: 17 nM for human EP4 receptor), more selective over EP1, EP2, EP3, and IP receptor. KAG-308 suppresses colitis and promotes histological mucosal healing, which potently inhibits TNF-α production.
靶点活性	EP1 receptor (human):1410 nM（ki）, EP4 receptor (human):(EC50)17 nM, EP4 receptor (human):（ki）2.57 nM, EP3 receptor (human):160 nM(EC50), EP3 receptor (human):32.4 nM（ki）, EP2 receptor (human):1000 nM(EC50), EP2 receptor (human):1540 nM（ki）, IP receptor (human):52.9 nM（ki）
体外活性	KAG-308 shows effective agonist activity for human and mouse EP4 (EC50: 0.15 nM and 1.0 nM, respectively in the dual luciferase reporter assay). KAG-308 shows a Ki and EC50 values of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over human EP1 (Ki, 1410 nM; EC50, 1000 nM), EP2 (Ki, 1540 nM; EC50, 1000 nM), EP3 (Ki, 32.4 nM; EC50, 160 nM) and IP receptor (Ki, 52.9 nM; EC50, >10000 nM) [1].